Metraipolis › archive › dc_265d98dcfe6d

Mettl3-Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS — Europe PMC PMID:41417662

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41417662
DOI: 10.1002/advs.202501242
License (as archived): solo-consultazione
Archived: 2026-11-07T13:01:11.937Z
SHA-256 of the archived text: 1edc771d283742dcaeafdeda68aa95e348924345a2ee9c0aa89c3cf319c10193
Stable URL of this page: https://metraipolis.com/documento/dc_265d98dcfe6d

How to cite

Mettl3-Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS — Europe PMC PMID:41417662 — Europe PMC (en), https://europepmc.org/article/MED/41417662 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_265d98dcfe6d (Metraipolis archive dc_265d98dcfe6d, sha256 1edc771d283742dcaeafdeda68aa95e348924345a2ee9c0aa89c3cf319c10193)

BibTeX

@misc{dc265d98dcfe6d,
  title = {Mettl3-Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS — Europe PMC PMID:41417662},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41417662},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_265d98dcfe6d; sha256 1edc771d283742dcaeafdeda68aa95e348924345a2ee9c0aa89c3cf319c10193},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41417662. Agents can read the archived copy with the MCP tool read_document.